Skip to main content
300 Collins St Melbourne hello@pivot.net
Login Signup
Home Home

Main navigation

  • About
    • Senior Management
    • Leadership
    • Board of Directors
    • Advisors
    • Contact
  • Research & Development
    • Innovation Engine
    • Therapeutic Focus
    • Development Strategy
    • Scientific Presentations
  • Pipeline
    • RMC-4630 (SHP2)
    • RMC-5552 (mTORC1/4EBP1)
    • SOS1
    • RAS(ON) Inhibitors
  • Investors
  • Careers
background

Scientific Presentations

The information included below was provided in connection with a presentation or publication on the date indicated and is qualified as such. Revolution Medicines disclaims any duty to update these materials.

 

 

Publication / Presentation

August 17, 2023

Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS

Read more

Publication / Presentation

June 14, 2023

Optimizing RAS Inhibition with Dual Blockade of Oncogenic and Wild-Type RAS

Read more

Publication / Presentation

June 13, 2023

Combinations of Tri-complex KRAS(ON) Inhibitors with RAS Companion Inhibitors and Immunotherapies Improve Anti-tumor Activity and Abrogate Adaptive Resistance in Preclinical Tumor Models In Vivo

Read more

Publication / Presentation

April 18, 2023

Bi-steric mTORC1 inhibitors are superior to rapamycin and induce apoptotic cell death in tumor models with hyperactivated mTORC1

Read more

Publication / Presentation

April 17, 2023

Preclinical evaluation of RM-042, an orally bioavailable inhibitor of GTP-RAS, in models of pancreatic ductal adenocarcinoma

Read more
VIEW ALL
© Revolution Medicines, Inc.  |  700 Saginaw Drive, Redwood City, CA 94063
CCPA Notice | Privacy Policy
Get in touch with us